Table 1 Patient demographics, preoperative staging, and treatment of cancer cases
From: The taTME learning curve for mid-low rectal cancer: a single-center experience in China
Variable | Values |
|---|---|
Sex, n (%) | |
Male | 77 (74.0) |
Female | 27 (26.0) |
Age, mean ± SD | 61.5 ± 11.5 |
BMI, kg/m2, median (IQR) | 24.2 (22.2–26.0) |
Comorbidity, n (%) | |
Yes | 48 (46.2) |
No | 56 (53.8) |
ASA, n (%) | |
I | 9 (8.7) |
II | 77 (74.0) |
III | 18 (17.3) |
Neoadjuvant chemoradiation, n (%) | |
Yes | 51 (49.0) |
No | 53 (51.0) |
Previous abdominal surgery, n (%) | 21 (20.2) |
Distance from anal verge, mm, median (IQR) | 50.0 (40.0–66.8) |
Middle rectum, n (%) | 48 (46.2) |
Lower rectum, n (%) | 56 (53.8) |
Preoperative T stage, n (%) | |
T1 | 2 (1.9) |
T2 | 18 (17.3) |
T3 | 77 (74.0) |
T4 | 7 (6.7) |
Preoperative N stage, n (%) | |
N0 | 43 (41.3) |
N1 | 33 (31.7) |
N2 | 18 (17.3) |
NX | 10 (9.6) |
Preoperative M stage, n (%) | |
M0 | 99 (95.2) |
M1 | 5 (4.8) |
Preoperative CRM involvement, n (%) | 22 (21.2) |